Immunogen (NASDAQ: IMGN) reported Q1 EPS of ($0.39), $0.04 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $14.9 million versus the consensus estimate of $15.84 million.

For earnings history and earnings-related data on Immunogen (IMGN) click here.